ストックスクリーナーアプリを入手
4.62
3.12%
0.14
前日終値:
$4.48
開ける：
$4.48
24時間の取引高:
65,313
Relative Volume:
0.42
時価総額：
$79.37M
収益：
$35.58M
当期純損益:
$-17.89M
株価収益率:
-6.7712
EPS:
-0.6823
ネットキャッシュフロー:
$-17.74M
1週間 パフォーマンス:
-19.09%
1か月 パフォーマンス:
-17.06%
6か月 パフォーマンス:
+12.96%
1年 パフォーマンス:
-3.08%
1日の値動き範囲:
$4.47
$4.76
1週間の範囲:
$4.245
$5.96
52週間の値動き範囲:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
4.62 | 76.96M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - Business Wire
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - Bluefield Daily Telegraph
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge By Investing.com - Investing.com South Africa
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Canada
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC FilingForm 10-K - Stock Titan
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
VRCA: Revenue up 370% in 2025, net loss narrowed, debt repaid, and YCANTH sales nearly doubled - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
Verrica Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
FRAUD AND MANIPULATION—E.D. Pa.:... - VitalLaw.com
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan - MSN
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISI - GuruFocus
West Chester-based Verrica partner launches YCANTH in Japan - MSN
Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & Safe Capital Growth Tips - baoquankhu1.vn
Aug Highlights: Can Verrica Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Verrica Investors Gain Class Status Over Delayed FDA Approval - Bloomberg Law News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Sahm
Pharma Co. Investors Secure Class Cert. Over FDA Obstacles - Law360
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Verrica Pharmaceuticals at TD Cowen Conference: Strategic Insights - Investing.com
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):